和铂医药宣布免疫学研究领导者Kenneth M. Murphy博士加入公司科学顾问委员会

Harbour BioMed Appoints Immunology Research Leader

Kenneth M. Murphy, MD, PhD to its Scientific Advisory Board

(*Please scroll down for English news)

和铂医药今日宣布免疫学研究领导者Kenneth M. Murphy博士加入公司科学顾问委员会。Murphy博士是美国国家科学院院士和霍华德·休斯医学研究所的研究员，同时，他还是圣路易斯华盛顿大学病理学与免疫学首位尤金·奥皮百年荣誉教授。

Kenneth M. Murphy博士

“Murphy博士是一位杰出的免疫学家，拥有超过30年免疫学领域的专业研究和经验，引领了新一代免疫学领域的诞生。” 和铂医药创始人，董事长兼首席执行官王劲松博士说，“Murphy博士为和铂医药带来了免疫学方向的宝贵洞见，我们期待他为和铂研医药研发针对肿瘤与免疫性疾病下一代的创新疗法提供更多的指导。”

Murphy博士因其对免疫细胞遗传谱系分化及其可塑性的决定机制的研究而广受认可。他的实验室发现了多种控制T细胞、树突细胞与巨噬细胞分化的细胞因子和转录因子。他曾出版超过250篇学术刊著，在超过145场讲座上受邀演讲。他是《Immunity》、《International Immunology》、《European Journal of Immunology》等国际顶尖生物学术期刊的编委，同时还担任免疫学界的圣经《Janeway’s Immunobiology》一书的第一作者。他荣获众多权威奖项，其中包括美国纽约的癌症研究所为嘉奖其在基础免疫学领域的突出成就，而颁发的肿瘤免疫学界顶级大奖–威廉·科利奖。

Murphy博士拥有约翰霍普金斯大学医学院的医学博士和药理学博士学位。1989年，在圣路易斯华盛顿大学医学院完成病理学住院医生和分子免疫学博士后研究后，他留校任教至今。

和铂医药是一家聚焦于免疫性疾病（包括免疫与肿瘤免疫）领域的全球化的生物制药公司，目前已有多个创新药物进入临床开发阶段，最快的处于临床二期。公司利用其拥有全球专利的两个全人源抗体转基因小鼠平台（Harbour Mice™）研发针对肿瘤免疫和免疫性疾病的突破性创新疗法。和铂医药还通过与业务伙伴的多元化合作快速拓展其新药研发管线。更多信息，请访问 www.harbourbiomed.com

王悦

公共关系经理，和铂医药

021-53399018

Yue.wang@harbourbiomed.com

Harbour BioMed Appoints Immunology Research Leader Kenneth M. Murphy, MD, PhD to its Scientific Advisory Board

Harbour BioMed (“HBM”) announced today the appointment of Kenneth M. Murphy, MD, PhD, to the company’s scientific advisory board. Dr. Murphy, a member of the National Academy of Sciences and a Howard Hughes Medical Institute Investigator, is the Eugene Opie First Centennial Professor of Pathology and Immunology at Washington University.

Dr Kenneth M. Murphy

“Dr Murphy is a distinguished immunologist with more than 30 years of expertise and experience in the field of immunology,” said Dr Jingsong Wang, HBM’s Founder, Chairman and CEO. “He brings to HBM great insight into basic mechanisms of immune cell lineage that underlie the immune response. We look forward to many contributions in guiding our programs aimed at developing next-generation therapeutics for cancer and immunological diseases.”

Dr Murphy is widely recognized for his research into the mechanisms of immune cell lineage differentiation and for determining the plasticity of these processes. His laboratory has discovered multiple cytokines and transcription factors that regulate differentiation of T cells, dendritic cells and macrophages.He is an author on 250 publications and delivered more than 145 invited lectureships. He serves in editorial capacities at several publications including, Immunity, International Immunology, and the European Journal of Immunology, and he is the lead author of Janeway’s Immunobiology. He received numerous awards, such as William B. Coley Award for Distinguished Research in Basic Immunology.

Dr Murphy has spent his career at Washington University. He joined the university faculty in 1989 after completing a post-doctoral fellowship and pathology residency at the school. Dr Murphy holds a combined M.D./Ph.D. degree from Johns Hopkins University.

Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology andinflammatory diseases. The company is building its proprietary pipeline throughinternal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

The company’s discovery and development programs arecentered around its two patented transgenic mouse platforms for generating fully human monoclonal antibodies. Harbour BioMed also licenses the platformsto companies and academic institutions.The company has operations in Cambridge, Massachusetts; Rotterdam, TheNetherlands; and Shanghai, China. For more information, visit www.harbourbiomed.com.

Yue Wang

PR Manager, Harbour BioMed

021-53399018

Yue.wang@harbourbiomed.com